Search
Altropane
go.drugbank.com/drugs/DB04947InvestigationalBoston Life Sciences (BLS) is developing Altropane as a potential radio-imaging agent to be used with single photon emission tomography (SPECT), for the early diagnosis of Parkinson's disease (PD) and
Donislecel
go.drugbank.com/drugs/DB17961Approved[L47196] Donislecel was approved by the FDA on June 28, 2023, and is available under the brand name LANTIDRA from CellTrans Inc.[L47196] … [L47166,L47196] The approval of donislecel was based on the safety and effectiveness evaluated in 2 clinical trials with 30 type 1 diabetic patients.
Osemozotan
go.drugbank.com/drugs/DB05339ExperimentalMN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD).
Tocainide
go.drugbank.com/drugs/DB01056ApprovedWithdrawnAn antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels.
EDP1815
go.drugbank.com/drugs/DB16486Investigationalsuch as gastrointestinal behavior, atopic dermatitis, psoriasis, skin inflammation, and COVID-19. … EDP1815, was investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions
Butalbital
go.drugbank.com/drugs/DB00241ApprovedIllicit[A177754] Butalbital has a low degree of selectivity and a narrow therapeutic index. … As with other barbiturates, butalbital carries a risk of abuse or misuse potential, intoxication, hangover, tolerance, dependence, and overdosage possibly leading to death.
Lefamulin
go.drugbank.com/drugs/DB12825Approved[A183206] Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. … [L8093] This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration.
Clesrovimab
go.drugbank.com/drugs/DB18877Approvedto provide passive immunization against RSV infection as an alternative means of protection. … [A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233]
XL820
go.drugbank.com/drugs/DB05146InvestigationalXL820 is investigated for use/treatment in solid tumors. XL820 is a solid. The proteins that XL820 inhibit include platelet-derived growth factor receptor beta (PDGFR), mast/stem cell growth factor receptor KIT, vascular endothelial grow...
Modafinil
go.drugbank.com/drugs/DB00745ApprovedInvestigationalModafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy.